Cystadenocarcinoma, Papillary
"Cystadenocarcinoma, Papillary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.
| Descriptor ID |
D018283
|
| MeSH Number(s) |
C04.557.470.200.025.480.230 C04.557.470.590.480.230
|
| Concept/Terms |
Cystadenocarcinoma, Papillary- Cystadenocarcinoma, Papillary
- Cystadenocarcinomas, Papillary
- Papillary Cystadenocarcinoma
- Papillary Cystadenocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Papillary".
Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Papillary".
This graph shows the total number of publications written about "Cystadenocarcinoma, Papillary" by people in this website by year, and whether "Cystadenocarcinoma, Papillary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cystadenocarcinoma, Papillary" by people in Profiles.
-
Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis. Gynecol Oncol. 2021 01; 160(1):214-218.
-
Syringocystadenocarcinoma Papilliferum In Situ-Like Changes in Extramammary Paget Disease: A Report of 11 Cases. Am J Dermatopathol. 2016 Dec; 38(12):882-886.
-
The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol. 2006 Nov; 103(2):679-83.
-
Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):839-44.
-
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):533-9.
-
Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol. 2003 Dec; 91(3):470-5.
-
Expression of gamma-glutamyl transpeptidase in stage III and IV ovarian surface epithelial carcinomas does not alter response to primary cisplatin-based chemotherapy. Am J Obstet Gynecol. 1998 Aug; 179(2):363-7.
-
Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol. 1994 Apr; 53(1):84-92.